ENVB Enveric Biosciences, Inc. NASDAQ · United States

Enveric Biosciences (ENVB) news ENVB reverse split, delisting and going concern news

Company Updates · Aug 14, 2026

Enveric reports second quarter 2026 net loss of $3.0 million

The company reported cash-on-hand of $8.3 million as of June 30, 2026, and an update on its lead candidate EB-003 ahead of an IND submission.

Latest Enveric Biosciences news

Jun 9, 2026Financings
Enveric files $2,425,000 at-the-market offering supplement with H.C. Wainwright
The prospectus supplement adds $2,425,000 of common stock to an at-the-market agreement with H.C. Wainwright & Co., LLC, following $4,483,711.04 already sold under it.
May 29, 2026Listings
Enveric stockholders vote on reverse split range and larger authorized share count
The 8-K reports the May 28, 2026 annual meeting vote counts, including a reverse split ratio of 1-for-5 to 1-for-15 set at the Board's discretion.
May 15, 2026Company Updates
Enveric reports first quarter 2026 net loss of $1.6 million
The company reported cash-on-hand of $4.9 million at March 31, 2026, and a cash balance of approximately $10.3 million as of May 15, 2026.
Apr 30, 2026Listings
Enveric corrects reverse split maximum in proxy materials to 1-for-15
A proxy supplement corrects a typographical error that showed a 1-for-50 maximum on the proxy card and notice before the May 28, 2026 annual meeting.
Apr 16, 2026Financings
Enveric announces up to $13.9 million private placement priced at-the-market
The company agreed to sell 2,222,223 shares at $2.25 per share with warrants, for about $5 million upfront, with H.C. Wainwright & Co. as placement agent.
Oct 23, 2025Listings
Enveric Biosciences gets Nasdaq delisting notice, sets 1-for-12 reverse split
Nasdaq said Enveric's stock closed below $1.00 for 30 consecutive trading days and the company has no compliance period. It plans to request a hearing and will split its shares 1-for-12 on October 28, 2025.
Aug 29, 2025Listings
Enveric Biosciences gets Nasdaq stockholders' equity deficiency notice, plan due October 10, 2025
Nasdaq says Enveric does not meet the $2,500,000 minimum stockholders' equity requirement. The company reported stockholders' equity of $2,184,769 in its latest 10-Q and has until October 10, 2025 to file a compliance plan.
Aug 29, 2025Listings
Enveric Biosciences falls short of Nasdaq $2,500,000 stockholders' equity rule
Nasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq Capital Market. Enveric has until October 10, 2025 to submit a plan to regain compliance.
Feb 3, 2025Financings
Enveric Biosciences prices $5 million public offering at $3.00 per share
H.C. Wainwright & Co. is the exclusive placement agent for a $3.00 offering of shares and warrants. The auditor's report on the 2023 financial statements already raised substantial doubt about the company's ability to continue as a going concern.

What Enveric Biosciences does

Enveric Biosciences, Inc. is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB-003, is a novel derivative of N,N-Dimethyltryptamine (DMT) designed to selectively engage both 5-HT 2A and 5-HT 1B receptors, with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects without hallucinogenic effects. EB-003 is in preclinical studies and has completed short-term dose-range finding toxicology studies. The company plans IND-enabling studies before first-in-human trials for depression or other neuropsychiatric disorders. Its lead program is the EVM301 Series. A second series, EVM401, was unveiled on February 25, 2025 to pursue additional non-hallucinogenic molecules for addiction and neuropsychiatric disorders. The Psybrary library of phenylalkylamine and indolethylamine compounds is covered by 20 patent families. Enveric licensed its EVM201 portfolio to MycoMedica Life Sciences, PBC on November 7, 2024, and the text says no term sheets for Psybrary molecules are pending.

Product or program	What it is	Stage
EB-003	Non-hallucinogenic DMT derivative for mental health indications	Preclinical
EVM401 Series	Additional non-hallucinogenic molecules for addiction and neuropsychiatric disorders
Psybrary library	Phenylalkylamine and indolethylamine compound library for neuroplastogens

Summarised from the company's 10-K filed Mar 27, 2026.

Enveric Biosciences annual financials

Line	FY2025	FY2024
Research and development	$2.8 million	$2.8 million
Net income (loss)	-$8.8 million	-$9.6 million
Cash from operations	-$8.1 million	-$7.7 million

Latest balance sheet, Dec 31, 2020 (10-K): cash and equivalents $1.6 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Enveric Biosciences

Did Enveric Biosciences do a reverse stock split?

Our latest story on this, dated May 29, 2026: "Enveric stockholders vote on reverse split range and larger authorized share count". The story links the filing or release it is based on. Read the story.

Was Enveric Biosciences delisted?

Our latest story on this, dated Oct 23, 2025: "Enveric Biosciences gets Nasdaq delisting notice, sets 1-for-12 reverse split". The story links the filing or release it is based on. Read the story.

Has Enveric Biosciences issued a going-concern warning?

Our latest story on this, dated Feb 3, 2025: "Enveric Biosciences prices $5 million public offering at $3.00 per share". The story links the filing or release it is based on. Read the story.

Has Enveric Biosciences raised money recently?

Our latest story on this, dated Jun 9, 2026: "Enveric files $2,425,000 at-the-market offering supplement with H.C. Wainwright". The story links the filing or release it is based on. Read the story.

Has Enveric Biosciences received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 29, 2025: "Enveric Biosciences gets Nasdaq stockholders' equity deficiency notice, plan due October 10, 2025". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Enveric Biosciences?

Enveric Biosciences, Inc. trades under the ticker ENVB on NASDAQ.

Where is Enveric Biosciences listed?

Enveric Biosciences, Inc. is listed on NASDAQ.

What is the SEC CIK of Enveric Biosciences?

The SEC Central Index Key (CIK) for Enveric Biosciences, Inc. is 890821. Its filings are on SEC EDGAR.

How many shares does Enveric Biosciences have outstanding?

4,475,884 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Enveric Biosciences listed under?

Our directory records Enveric Biosciences, Inc. under United States.

What does Enveric Biosciences do?

Our directory classifies Enveric Biosciences, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.

What is the ISIN of Enveric Biosciences?

The ISIN recorded for Enveric Biosciences, Inc. is US29405E5050.

Does aibio.space cover Enveric Biosciences?

aibio.space lists Enveric Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Enveric Biosciences incorporated?

SEC records list its state or country of incorporation as DE.

What does Enveric Biosciences develop?

Investor discussion: Enveric Biosciences

Members talk about Enveric Biosciences (ENVB). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Enveric Biosciences, newest first. Each line links the filing it comes from.

May 29, 2026Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Apr 30, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Apr 20, 2026Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Apr 14, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Apr 3, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Mar 27, 2026Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Feb 10, 2026Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Jan 28, 2026Financings
Reported a financing. SEC Form 424B5. Source
Dec 11, 2025Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Nov 14, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Oct 27, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Oct 23, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,8.01,9.01). Source
Oct 10, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Aug 29, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Jun 3, 2025Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Apr 15, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Apr 14, 2025Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Apr 4, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Mar 28, 2025Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Mar 6, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Feb 3, 2025Financings
Reported a financing. SEC Form 424B4. Source
Jan 21, 2025Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). Source
Jan 14, 2025Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Dec 18, 2024Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Nov 27, 2024Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Nov 22, 2024Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ENVB on TradingView.

SEC filings and registration

SEC name: Enveric Biosciences, Inc.
CIK: 890821
Industry (SIC): Pharmaceutical Preparations (2834)
US tickers: ENVB (Nasdaq)
State or country of incorporation: DE
Fiscal year ends: December 31
Filer category: Non-accelerated filer<br>Smaller reporting company
Business address: 245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
Phone: (617) 444-8400
Shares outstanding: 4,475,884 as of 2026-08-12 (10-Q filed 2026-08-14)
Former names: AMERI Holdings, Inc.; SPATIALIZER AUDIO LABORATORIES INC

Recent filings (8-K and 6-K are the company's own announcements)

10-Q filed 2026-08-14
8-K filed 2026-08-14
8-K filed 2026-06-09
424B5 filed 2026-06-09
8-K filed 2026-06-09
8-K filed 2026-05-29
10-Q filed 2026-05-15
8-K filed 2026-05-15

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Enveric Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ENVB, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: Enveric Biosciences, Inc.
Ticker: ENVB
Listing: NASDAQ
Country or territory: United States
Business scope: Biopharma / pharmaceutical profile checked
ISIN: US29405E5050
Last quote in directory: 2026-10-21
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction